Patients with Down syndrome can be included in early phase clinical trials- a report from the T2016-003 Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) study-Reference-Cited by-同舟云学术

Patients with Down syndrome can be included in early phase clinical trials- a report from the T2016-003 Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) study

Published:2023-02-22 Issue:5 Volume:37 Page:1138-1140
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Gossai N.^ORCID,Bhojwani D.^ORCID,Schafer E. S.,Chang B. H.^ORCID,Pommert L.^ORCID,Verma A.^ORCID,Malvar J.,Chi Y. Y.,Hitzler J.^ORCID,Burke M. J.^ORCID,Rabin K. R.

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

https://www.nature.com/articles/s41375-023-01856-6.pdf

Reference13 articles.

1. Robison LL. Down syndrome and leukemia. Leukemia. 1992;6 Suppl 1:5–7.

2. Taga T, Saito AM, Kudo K, Tomizawa D, Terui K, Moritake H, et al. Clinical characteristics and outcome of refractory/relapsed myeloid leukemia in children with Down syndrome. Blood 2012;120:1810–5.

3. Hitzler JK, He W, Doyle J, Cairo M, Camitta BM, Chan KW, et al. Outcome of transplantation for acute myelogenous leukemia in children with Down syndrome. Biol Blood Marrow Transplant. 2013;19:893–7.

4. Meyr F, Escherich G, Mann G, Klingebiel T, Kulozik A, Rossig C, et al. Outcomes of treatment for relapsed acute lymphoblastic leukaemia in children with Down syndrome. Br J Haematol. 2013;162:98–106.

5. Taub JW, Berman JN, Hitzler JK, Sorrell AD, Lacayo NJ, Mast K, et al. Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children’s Oncology Group AAML0431 trial. Blood. 2017;129:3304–13.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Down syndrome-associated leukaemias: current evidence and challenges;Therapeutic Advances in Hematology;2024-01

2. Down syndrome and leukemia: An insight into the disease biology and current treatment options;Blood Reviews;2023-11